Mylan expands cancer drug recall on particle contamination worries

Companies are eyeing sterile injectable drugs for growth, but the formulas are notoriously tricky to manufacture. Mylan ($MYL) has found that out the hard way, and it's now expanding a recall of cancer drugs that it began in April because they may contain particulate. Some of the drugs were manufactured for Pfizer ($PFE). More from FiercePharmaManufacturing

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.